Blog
RSS FeedPosted by Michael Wonder on 28 Nov 2019
Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund
28 November 2019 - Around 3,200 women in England could be eligible for treatment. ...
Posted by Michael Wonder on 26 Nov 2019
Mavenclad granted accelerated access by NICE
26 November 2019 - Merck has announced good news for some multiple sclerosis patients, as its Mavenclad (cladribine) has been ...
Posted by Michael Wonder on 14 Nov 2019
NICE ‘OK’ for Sativex in MS
14 November 2019 - NICE has recommended Bayer’s Sativex (delta-9 tetrahydrocannabinol cannabidiol), for spasticity in people with multiple sclerosis. ...
Posted by Michael Wonder on 13 Nov 2019
NICE recommends Elmiron for bladder pain syndrome
13 November 2019 - NICE has recommended Consilient Health’s Elmiron (pentosan polysulfate sodium) for bladder pain syndrome. ...
Posted by Michael Wonder on 13 Nov 2019
NICE during the pre-election period
12 November 2019 - As a public body, NICE is required to follow civil service principles on communicating during the lead ...
Posted by Michael Wonder on 11 Nov 2019
NICE U-turn for Epidyolex in epilepsy
11 November 2019 - GW Pharma has announced that NICE has recommended Epidyolex (cannabidiol) for two rare, severe forms of ...
Posted by Michael Wonder on 31 Oct 2019
NICE terminates another two assessments for cancer medicines
30 October 2019 - One medicine is from Janssen; the other is from Eli Lilly. ...
Posted by Michael Wonder on 11 Oct 2019
Another treatment option for ovarian cancer approved for the Cancer Drugs Fund
11 October 2019 - An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE ...
Posted by Michael Wonder on 10 Oct 2019
Elmiron bags draft NICE approval
10 October 2019 - NICE has published a draft final appraisal regarding Elmiron (pentosan polysulfate sodium) for bladder pain syndrome. ...
Posted by Michael Wonder on 26 Sep 2019
Migraine drug not cost effective NICE says in final draft guidance
26 September 2019 - NICE has said that a new drug for preventing migraine is not a cost effective use of ...
Posted by Michael Wonder on 25 Sep 2019
NICE terminates another three assessments
25 September 2019 - NICE has terminated 11 assessments so far this year. ...
Posted by Michael Wonder on 18 Sep 2019
NICE recommends Takhzyro
18 September 2019 - NICE - a health technology appraisal body in England and Wales - has recommended the use ...
Posted by Michael Wonder on 11 Sep 2019
NICE publishes its 600th technology appraisal guidance
12 September 2019 - The guidance relates to the use of pembrolizumab in combination with carboplatin and paclitaxel on the ...
Posted by Michael Wonder on 04 Sep 2019
NHS funds eye gene therapy, after Novartis cuts £613,000 price
4 September 2019 - NICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the ...
Posted by Michael Wonder on 04 Sep 2019
NICE recommends novel gene therapy treatment for rare inherited eye disorder
4 September 2019 - It's estimated that 86 people would be eligible for treatment with voretigene neparvovec in England. ...